Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures
This study has been completed.
Study NCT00004817   Information provided by Office of Rare Diseases (ORD)
First Received: February 24, 2000   Last Updated: June 23, 2005   History of Changes

February 24, 2000
June 23, 2005
February 1991
 
 
 
Complete list of historical versions of study NCT00004817 on ClinicalTrials.gov Archive Site
 
 
 
Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures
 

OBJECTIVES: I. Determine whether treating head injured patients with valproate sodium will reduce the risk of developing seizures as a result of the head injury.

II. Determine the safety of valproate, the appropriate dose, and the effect valproate may have on the recovery of the brain's ability to compute numbers, solve problems, remember information, and control the movement of limbs after head injury.

PROTOCOL OUTLINE: This is a randomized, double blind trial involving 3 treatment groups.

On day 1, controls receive phenytoin IV over 1 hour. On days 2 through 7, controls receive 2 doses each of phenytoin and placebo daily, intravenously. From day 8 through 6 months, controls receive placebo IV 4 times daily, then placebo tablets are administered.

On day 1, the experimental group receives a loading dose of valproate sodium intravenously over 1 hour within 24 hours of injury. Then, patients are divided into 2 subgroups.

From day 2 through 1 month, one group of patients receives valproate IV 4 times daily over 1 hour until tablets are tolerated. Patients receive placebo tablets by mouth 4 times daily from month 2 through month 6.

On day 2, the other group of patients receives valproate IV 4 times daily and continues for 6 months until tablets (same dose) are tolerated.

If patients remain seizure free between day 8 and 6 months, the number of valproate or placebo tablets are tapered over 1 week.

Each patient receives a full neuropsychological and psychosocial examination at 1, 6, and 12 months after injury.

Untreated observation of patients continues until 2 years after injury.

Phase III
Interventional
Treatment
  • Post-Traumatic Seizure Disorder
  • Head Injuries
  • Drug: phenytoin
  • Drug: valproate sodium
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
385
 
 

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Any patient developing the following conditions within 24 hour postinjury:

  • Cortical contusion
  • Depressed skull fracture
  • Subdural hematoma
  • Epidural hematoma
  • Intracerebral hematoma
  • Penetrating head wound
  • Seizures occurring subsequent to head injury

--Prior/Concurrent Therapy--

  • No antiseizure medication prior to injury or between the injury and study drug loading
  • Surgery: No prior neurosurgical operation for which the skull and dura mater were opened

--Patient Characteristics--

  • Age: 14 and over
  • Hematopoietic: No abnormal coagulation profile
  • Hepatic: No history of chronic or alcoholic liver disease Adequate liver function as indicated by ALT less than 1.5 times the upper limit of normal
  • Other: Not pregnant No injuries greater than 24 hours old No history of seizures prior to injury No prior history of significant head injury or neurological condition requiring medical attention
Both
14 Years and older
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00004817
 
199/12249, UW-19643
National Institute of Neurological Disorders and Stroke (NINDS)
Harborview Injury Prevention and Research Center
Study Chair: H. Richard Winn Harborview Injury Prevention and Research Center
Office of Rare Diseases (ORD)
December 2001

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP